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ABSTRACT 
Although the clinical manifestations of cardiovascular disease (CVD), such as myocardial infarction, stroke, and 
peripheral vascular disease, appear from middle age, the process of atherosclerosis can begin early in childhood. 
The early stage and progression of atherosclerosis in youth are influenced by risk factors that include obesity, 
hypertension, dyslipidemia, and smoking, and by the presence of specific diseases, such as diabetes mellitus and 
Kawasaki disease (KD). The existing evidence indicates that primary prevention of atherosclerotic disease should 
begin in childhood. Identification of children at risk for atherosclerosis may allow early intervention to decrease 
the atherosclerotic process, thereby preventing or delaying CVD. This review will describe the origin and pro-
gression of atherosclerosis in childhood, and the identification and management of known risk factors for athe-
rosclerotic CVD in children and young adults. (Korean Circ J 2010;40:1-9) 
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Introduction 
 
Although atherosclerosis manifests clinically in mid-
dle and late adulthood, it is well-known that it has a 
long asymptomatic phase of development, which begins 
early in life, often during childhood. In most children, 
atherosclerotic vascular changes are minor and can be 
minimized or prevented with a healthy lifestyle. How-
ever, in some children the process is accelerated because 
of risk factors or specific diseases. Identification of child-
ren who are at risk for atherosclerosis may allow early 
intervention to decrease the atherosclerotic process, pre-
venting or delaying cardiovascular diseases (CVD), such 
as myocardial infarction, stroke, and peripheral vascular 
disease. 
 
Atherosclerotic Changes in Childhood 
 
Atherosclerosis begins in childhood as an accumula-
tion of fatty streaks-lipid-engorged macrophages (foam 
cells) and T lymphocytes in the intima of the arteries. 
Fatty streaks may or may not progress, and may regress. 
In some people, lipid accumulation is more pronounc-
ed with time, and the accumulated lipid becomes co-
vered by a fibromuscular cap to form what is termed a 
fibrous plaque. Temporally, between the fatty streak and 
the fibrous plaque, transitional stages of atherosclero-
sis exist that are not identifiable by gross examination 
alone. With time, fibrous plaques enlarge and undergo 
calcification, hemorrhage, ulceration or rupture, and 
thrombosis. Thrombotic occlusion precipitates clinical 
disease such as myocardial infarction, stroke, or gan-
grene depending on which artery is affected (Fig. 1).
1)  
As detailed below, autopsy studies in children and 
young adults who had died of non-cardiovascular cau-
ses have conclusively demonstrated early development 
of atherosclerosis.   
Attention was first drawn to the early origin of athe-
rosclerosis by an autopsy study conducted on young 
soldiers killed in the Korean War.
2) Their average age 
was 22 years, and over 70% of them had evidence of 
atherosclerosis in their coronary arteries. Postmortem 
coronary angiography and dissection of hearts from 
105 United States soldiers killed in Vietnam demon-
strated that 45% had some evidence of atherosclerosis 
and 5% had gross evidence of severe coronary athe-
rosclerosis.
3) Another study demonstrated a very high 
incidence of lipid-laden macrophages in the intima of 
the aorta and coronary arteries of young American 
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children killed in motor accidents, with over 50% of 
children aged 10-14 years having some evidence of early 
atherosclerosis.
4) A nation-wide autopsy-based study of 
atherosclerosis in young Japanese (1 month-39 years) 
disclosed the presence of fatty streaks in 29% of aortas 
in those aged <1 year and in 3.1% of coronary arteries 
of children aged 1-9 years.
5) Another examination 13 
years later revealed an increased prevalence and extent 
of coronary artery lesions in autopsied subjects who 
died in their third and fourth decade of life.
6) In the 
Bogalusa Heart Study,
7) the extent of fatty streaks and 
fibrous plaques in the aorta and coronary arteries were 
examined in 204 young patients 2-39-years-of-age. The 
prevalence of fatty streaks in the coronary arteries in-
creased with age from approximately 50% at 2-15-years-
of-age to 85% at 21-39-years-of-age, and the prevalence 
of raised fibrous-plaque lesions increased with age from 
8% at 2-15-years-of-age to 69% at 26-39-years-of-age. 
The prevalence and the extent of atherosclerosis was gr-
eater with increasing age, body mass index (BMI), blood 
pressure, and levels of serum total cholesterol (TC) and 
low-density lipoprotein cholesterol (LDL-C). The degree 
of involvement increased with worsening severity and 
greater numbers of risk factors. In the Pathobiological 
Determinants of Atherosclerosis in Youth (PDAY) st-
udy,
8) the right coronary arteries and aortas were ex-
amined during autopsy in 2,876 individuals aged 15-34 
years. Raised fatty streaks were present in the abdomi-
nal aortas of approximately 20% of those aged 15-19 
years and approximately 40% of subjects 30-34-years-
of-age, and in the right coronary arteries of approxi-
mately 10% of 15-19-year-old subjects and approxima-
tely 30% of those aged 30-34 years at the time of death. 
The percent of intimal surface involved with raised fat-
ty streaks increased with age and was associated with a 
high level of non-high-density lipoprotein cholesterol 
(HDL-C) and low HDL-C, hypertension, obesity, and 
impaired glucose tolerance. An intravascular ultrasound 
study determined that 17% of otherwise healthy heart 
donors <20 years of age, 37% of those aged 20-29 years, 
60% of those aged 30-39 years, 71% of those aged 40-
49 years, and 85% of those ≥50-years-of-age had evid-
ence of coronary atherosclerosis.
9) 
 
Noninvasive Assessment   
of Preclinical Atherosclerosis 
 
Until recently, our understanding of the childhood 
antecedents of adult CVD was limited mainly to auto-
psy studies and pathologic findings in teenagers and 
young adults who died from accidental causes. Recent 
advances in noninvasive techniques have allowed de-
tection of early changes in physiology and visualization 
of anatomical and mechanical abnormalities that re-
flect the preclinical biology of atherogenesis.   
In adults, noninvasive measures of atherosclerosis 
have become established as valid and reliable tools for 
refining the cardiovascular risk to target individuals who 
need early intervention. Noninvasive ultrasound studies 
of the neonatal aorta and fetal and early childhood 
postmortem studies indicate that impaired fetal growth, 
in utero exposure to maternal hypercholesterolemia, and 
diabetic macrosomia may all be important risk factors 
for vascular changes consistent with the earliest physi-
cal signs of atherosclerosis.
10) With limited pediatric data, 
the use of these techniques in children and adolescents 
largely has been reserved for research purposes.
11)  
 
Functional measures 
Endocardial function can be evaluated by measuring 
changes in blood vessel diameter in response to speci-
fic stimuli using the technique of flow-mediated dila-
tion (FMD). FMD measures the nitric oxide-mediated 
vasodilation produced by increased flow after a period 
of ischemia (e.g., ischemia induced by an inflated blood 
pressure cuff) by brachial artery ultrasonography. Ab-
normalities in endothelial function have been noted in 
children affected with a variety of conditions. Decreas-
ed FMD has been observed in children with type 1 dia-
betes mellitus, a family history of premature coronary 
disease,
12) and Kawasaki disease (KD).
13)14)  
 
Structural measures 
Carotid intima-media thickness (cIMT) has been used 
extensively in children and young adults with risk fac-
tors for CVD. Several large studies have shown that in-
creased IMT correlates well with traditional cardiovas-
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cular risk factors that include excess weight, dyslipide-
mia, and hypertension.
15-17) In addition, increased IMT 
is found in adolescents with familial hyperlipidemia and 
in children with a parent with a history of premature 
myocardial infarction.
12)18) Young adults with increased 
IMT have an increased likelihood of a cardiovascular 
events that include myocardial infarction and stroke.   
In addition to cIMT, some pediatric studies have meas-
ured IMT in the aorta (aIMT). This technique has proved 
useful even in neonates and young children. Increased 
aortic wall thickness has been associated with low birth 
weight,
19) intrauterine growth restriction,
20) maternal 
smoking,
21) and familial hypercholestrolemia.
22)  
The combined thickness of carotid artery intima and 
media is associated with coronary heart disease risk fac-
tors. The intima is more directly involved in atherosc-
lerosis than the media, and the thickness of the intima 
alone measured by high-resolution ultrasonography may 
aid in detecting early vascular changes of atherosclerosis.
23) 
Serum LDL-C level may be more closely associated 
with the carotid intimal thickness than IMT for pa-
tients with coronary atherosclerosis.
24)  
Arterial stiffness can be assessed noninvasively by 
measuring a parameter known as the pulse wave velo-
city (PWV) between two major arteries located in the up-
per body (i.e., carotid or brachial artery) and the lower 
body (i.e., femoral or ankle). PWV reflects the time 
needed for the pulse wave to travel a given distance along 
the blood vessel. Stiffer arteries produce a higher PWV. 
Arterial stiffness normally varies among adolescents 
and young adults based upon gender, age, and ethnicity. 
After adjusting for age and gender, arterial stiffness in 
adolescents and young adults is associated with CVD 
risk factors that include BMI, hypertension, and ele-
vations in serum triglyceride (TG), homocysteine, and 
fasting insulin concentrations.
25-27)  
PWV may have an advantage compared to other non-
invasive techniques in the primary care setting due to 
its simplicity of use and shorter time required for a meas-
urement.  
Computed tomography (CT) allows localization and 
quantification of calcium deposits in coronary arteries. 
However, the paucity of data regarding calcification in 
early atherogenesis, and the potentially harmful effects 
of early radiation exposure currently limits the clinical 
use of CT in children.   
Magnetic resonance imaging (MRI) is increasing be-
ing used to assess early atherosclerosis, since it allows 
characterization of cardiovascular structure, function, 
and blood flow without exposure to ionizing radiation. 
It has been used to measure atheromatous plaques and 
characterize structure in the peripheral circulation.   
Both CT and MRI are currently being combined with 
positron emission tomography and fluorescent imag-
ing to evaluate plaque biology in more detail.
28)  
Risk Factors for Atherosclerosis 
in Children 
 
In adults, large prospective population-based studies 
have shown that a higher risk of CVD is associated with 
multiple risk factors that include obesity, hypertension, 
dyslipidemia, diabetes, smoking, and family history of 
CVD. While data linking these risk factors to cardio-
vascular events are limited in children, these risk factors 
are associated with acceleration of atherosclerosis in 
children. These risk factors do not generally occur in 
isolation but are usually found concurrently.   
 
Overweight/Obesity 
The prevalence of children who are clinical overweight 
or obsess is increasing rapidly globally. Children and 
adolescents who are overweight/obese are more likely 
to be overweight/obese as adults. In autopsy studies, 
BMI was positively correlated with more extensive athe-
rosclerotic changes in the aorta and coronary arteries 
during childhood.
7)8)  
Childhood obesity raises the risk of other risk fac-
tors that are associated with heart disease in early ad-
ulthood, such as high blood pressure or diabetes melli-
tus. In one study, children between the ages of 6 and 
19 years with metabolic syndrome showed an increas-
ed risk of CVD {odds ration: 14.6, 95% confidence 
interval: 2.8-45.3} at 25 year follow-up compared to 
the general school population.
29) Generally, overweight 
children are inactive and may have obstructive sleep 
apnea, both of which are associated with CVD in adults. 
 
Hypertension  
Children and adolescents with hypertension are more 
likely to have hypertension as adults. In adults, hyper-
tension is a well-established risk factor for CVD that 
include myocardial infarction and stroke. Although si-
milar direct evidence linking hypertension with CVD 
is lacking, hypertension has been linked to increased 
IMT and arterial stiffness, suggestive of accelerated ath-
erosclerosis.  
 
Dyslipidemia  
Dyslipidemia is a disorder of lipoprotein metabolism 
that results in increased TC, high LDL-C, low HDL-C, 
and high TG. The National Cholesterol Education Pro-
gram (NCEP) defines dyslipidemia in children as values 
that are greater than the 95th percentile and defined 
cutoff points.
30) Subsequently, the National Health and 
Nutrition Examination Surveys (NHANES) presented 
age- and gender-specific lipoprotein threshold concen-
trations for adolescents.
31) The predictive capacity of both 
NCEP and NHANES cut points were similar predict-
ing high common carotid artery IMT in adulthood.
32) 
Adolescent lipid levels were more strongly associated  
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with high IMT in adulthood than change in lipid levels. 
Overweight or obese adolescents with dyslipidemia had 
increased cIMT in adulthood compared with those who 
did not have both risk factors, leading the authors to 
suggest that dyslipidemia screening could be limited to 
overweight or obese adolescents.   
Although dyslipidemia is an established risk factor 
for CVD in adults, no long-term studies directly link 
dyslipidemia in childhood with subsequent CVD, with 
the possible exception of children with monogenetic 
causes of dyslipidemia such as familial hypercholeste-
rolemia. Autopsy studies demonstrated an increase ath-
erosclerotic lesions in the coronary artery and aorta with 
increasing serum LDL-C and decreasing HDL-C.
7)8) In-
dividuals who displayed elevations in non-HDL-C, LDL-
C, and TC: HDL-C in children are more likely to have 
increased IMT in adulthood.
33)  
 
Family history   
A family history of CVD is an independent risk fac-
tor for coronary vascular events, especially in young 
adults. Children whose parents or grandparents had a 
heart attack or stroke at an early age have twice the 
risk of developing CVD in middle-aged adults.
34) He-
althy offsprings of parental history of premature acute 
myocardial infarction can present with lipid disturb-
ances and increased carotid IMT compared to healthy 
children with no parental history of coronary disease.
35) 
 
Smoking  
Smoking and passive exposure to tobacco smoke in-
creases the risk of CVD. Teenagers who smoke are likely 
to continue smoking into adulthood, thus increasing their 
risk of early CVD. Smoking is associated with a much gr-
eater extent of fatty streaks and raised lesions in the ab-
dominal aorta.
36) Although the mechanisms in cigarette 
smoking-related cardiovascular dysfunction are largely 
unknown, smoking increases inflammation, thrombosis, 
and oxidation of LDL-C. Recent experimental and cli-
nical data support the hypothesis that cigarette smoking 
exposure increases oxidative stress as a potential mecha-
nism for initiating cardiovascular dysfunction.
37)  
 
Hyperglycemia  
Hyperglycemia is strongly associated with the extent 
of fatty streaks and raised lesions in both the coronary 
artery and the abdominal aorta.
38) Increased IMT has 
been documented in children with type 1 diabetes.
39)  
 
High-Risk Diseases 
 
Pediatric diseases or events associated with high-risk 
for CVD include familial hypercholesterolemia, types 
1 and 2 diabetes mellitus, chronic kidney disease, car-
diac transplantation, KD, chronic inflammatory disease, 
survivors from childhood cancer, and congenital heart 
disease. The American Heart Association has issued 
recommendations for cardiovascular risk management 
in these high-risk diseases.
40)41) 
 
Risk Assessment 
 
In adults without known CVD, a multivariable as-
sessment is used to estimate their risk for cardiovas-
cular events and to guide therapeutic choices aimed at 
risk reduction (Framingham Risk Score). No such sys-
tem is used in clinical pediatric practice. As described 
Table 1. PDAY risk score for predicting advanced atherosclero-
tic lesions in coronary arteries 
Risk factors  Coronary Artery Risk Scores
Immutable risk factors   
Age (years)   
15-19 0 
20-24 5 
25-29 10 
30-34 15 
Sex  
Male 0 
Female  -1 
Modifiable risk factors   
Non-HDL-C (mg/dL)   
<130 0 
130-159 2 
160-189 4 
190-219 6 
≥220 8 
HDL-C (mg/dL)   
<40 1 
40-59 0 
≥60  -1 
Smoking  
Nonsmoker 0 
Smoker 1 
Blood pressure   
Normotensive 0 
Hypertensive 4 
Obesity (BMI)   
Men  
BMI ≤30 kg/m
2 0 
BMI >30 kg/m
2 6 
Women  
BMI ≤30 kg/m
2 0 
BMI >30 kg/m
2 0 
Hyperglycemia  
Glycohemoglobin <8% 0 
Glycohemoglobin ≥8% 5 
Adapted from McMahan et al.
43) PDAY: Pathobiological Determi-
nants of Atherosclerosis in Youth, HDL-C: high-density lipoprotein 
cholesterol, BMI: body mass index 
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below, a grading system has been proposed based on 
data from the PDAY study.
42)43)  
 
Pathobiological Determinants 
of Atherosclerosis in Youth Risk Scores 
 
The PDAY study of autopsy findings in young peo-
ple developed a risk score that provides a simple way to 
calculate weighted effects of the major established risk 
factors on atherosclerosis (Table 1). Risk scores com-
puted from the modifiable risk factors were associated 
with prevalence of microscopically demonstrable lesions 
of atherosclerosis and with the extent of the earliest 
detectable gross lesion (fatty streaks) in the coronary ar-
tery and aorta. When tested in young persons in the 
Coronary Artery Risk Development in Youth Adults 
(CARDIA) study, this risk score predicted calcium in 
the coronary arteries as long as 15 years after the risk 
factors were measured.
44) 
The severity of childhood atherosclerosis increases 
as the number of CVD risk factors. Children with one 
or more known atherosclerotic risk factors should be 
screened for additional risk factors. Fig. 2 shows the es-
timated probability of advanced atherosclerotic lesions 
in the coronary arteries by the PDAY modifiable risk 
score (5-year age group for men and women).
43) 
 
Screening Tests 
 
Screening every child with tests to look for atherosc-
lerosis risk factors is not currently recommended. The 
most current recommendation is to screen children and 
adolescents who have one or more of the following risks: 
•Family history of early CVD (before age 55 for men 
and 65 for women), high cholesterol, high lipids, or 
diabetes 
•Overweight/obesity, hypertension, dyslipidemia, and 
insulin resistance 
•High-risk diseases (as summarized above)  
The first screening should take place after 2 years of 
age but no later than 10 years of age. The following sc-
reening items should be included:  
Table 2. Guidelines for diet, smoking and physical activity for children
Diet 
• Balance calorie intake and physical activity to achieve or maintain a healthy body weight   
• Consume a diet rich in vegetables and fruits 
• Choose whole-grain, high-fiber foods 
• Consume fish, especially oily fish, at least twice a week (omega-3 fatty acids)   
• Limit your intake of saturated fats to <7% of energy, cholesterol to <300 mg per day, and trans fat to <1% of energy 
• Minimize intake of beverages and foods with added sugars 
• Choose and prepare foods little or no salts (sodium intake <2.3 g/d) 
• If you consume alcohol, do so in moderation   
Smoking 
• Question tobacco use by parents at every visit 
• Question tobacco use by children at every visit starting at age 10   
• Advise avoidance of second-hand smoke at home, with friends, at school, or at work   
Physical activity 
• Advise young people to participate in at least 60 minutes of moderate to vigorous physical activity every day 
• Physical activity should be fun for children and adolescents 
• For adolescents, resistance training (10-15 repetitions at moderate intensity) can be combined with aerobic activity in an overall activity program 
• Sedentary time should be limited. For example, limit television time to at most 2 hours per day 
 
Fig. 2. Estimated probability of advanced atherosclerotic lesions in the coronary arteries by PDAY risk scores. PDAY: Pathobiological De-
terminants of Atherosclerosis in Youth. 
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• Blood pressure (on three separate occasions)  
• Calculation of BMI   
• Fasting lipid profile   
• Fasting blood sugar   
• Exercise, diet, and sleep   
• History of smoking and smoke exposure   
 
Primary Prevention of Atherosclerotic 
Cardiovascular Disease in Childhood  
 
The existing evidence indicates that primary preven-
tion of atherosclerotic CVD should begin in childhood. 
It would be most effective to control risk factors early 
in life. The following guidelines are based on the re-
commendations by the American Heart Association 
(AHA).
40)41)45-47)  
 
Guidelines for cardiovascular health promotion to 
all children   
Guidelines for diet, physical activity and smoking
45)46) 
are summarized in Table 2.   
 
Guidelines for cardiovascular risk reduction in ch-
ildren and adolescents with identified risk   
Guidelines for cardiovascular risk reduction in children 
and adolescents with identified risk are summarized in 
Table 3. Guidelines for cardiovascular risk reduction in children and adolescents with identified risk
Dyslipidemia 
Definition 
• TC >200 mg/dL (5.18 mmol/L)   
• LDL-C >130 mg/L (3.36 mmol/L) 
• HDL-C <40-45 mg/dL (1.0 mmol/L)   
• TG >150 mg/dL (1.7 mmol/L) in adolescents, >130 mg/dL (1.47 mmol/L) in younger children   
Nonpharmacologic therapy   
• Dietary intervention and increased activity at least for 6-12 months, then repeat LDL measurement   
Pharmacologic therapy 
• If nonpharmacologic therapy does not decrease cholesterol levels sufficiently after 6-12 months, or if a child’s cholesterol or TG levels 
are high, one or more medication may be recommended   
Hypertension 
Definition  
• Hypertension: >95th percentile   
• Prehypertension: 90-95th percentile   
Nonpharmacologic therapy   
• Diet and increased activity 
- Reduce sodium in the diet 
- Increased fruits and vegetables   
- Evaluate for secondary causes (e.g., renal diseases, coarctation of aorta)   
Pharmacologic therapy   
• If the BP persists above the targeted goal despite nonpharmacologic therapy: antihypertensive medication started 
• For children with severe hypertension (5 mmHg greater than the 99th percentile) and those with hypertensive target-organ damage 
(e.g., left ventricular hypertrophy) or high risk diseases (Table 2) with blood pressure above the 95th percentile: pharmacologic therapy 
started.  
Overweight or obesity 
Definition  
• Overweight: BMI >85th percentile   
• Obesity: >95th percentile   
Treatment  
• Lifestyle changes   
• Nutrition education: diet, weight follow-up every 2-4 weeks for 6 months 
• Activity counseling   
• If BMI still elevated, weight management program   
• Match energy needs for normal growth and development 
• Maintain weight or slow rate of weight gain for younger children to achieve healthy BMI with growth in height   
• Gradual weight loss (1-2 kg/mo) in overweight adolescents or in very overweight younger children or in those with co-morbid conditions 
Insulin resistance and diabetes mellitus 
Insulin resistance 
• Fasting glucose=100-126 mg/dL: calorie-reduced diet, increased activity aimed at 5-10% decrease in weight over 6 months   
• If repeated fasting glucose=100-126 mg/dL: Insulin-sensitizing medication as prescribed by an endocrinologist   
Diabetes mellitus 
• Casual glucose >200 mg/dL or fasting glucose >126 mg/dL: endocrine referral for evaluation and management 
• Maintain glycated hemoglobin <7% 
TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, TG: triglyceride, BP: blood pres-
sure, BMI: body mass index    
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Table 3.
45)46) 
 
Management of Children and 
Adolescents With High-Risk Diseases 
 
Certain pediatric disease states are associated with 
dramatically accelerated atherosclerosis, with clinical 
coronary events occurring in childhood or very early 
adult life. Intensive cardiovascular risk reduction is of 
critical importance in such children. The AHA deve-
loped recommendations for cardiovascular risk mana-
gement in high-risk pediatric settings. The recommen-
Table 4. Disease stratification by risk 
  Risk category  Rationale  Disease process/Condition 
Tier I  High risk  Manifest CAD <30 years of age: 
 clinical  evidence 
Homozygous familial hypercholesterolemia (FH) 
Diabetes mellitus, type 1 
Chronic kindey disease (CKD)/end-stage renal disease (ESRD)
Post-orthotopic heart transplantation (OHT) 
Kawasaki disease, current coronary aneurysms 
Tier II  Moderate risk  Accelerated atherosclerosis: 
 pathophysiological  evidence 
Heterozygous FH 
Kawasaki disease with regressed coronary artery aneurysms 
Diabetes mellitus, type 2 
Chronic inflammatory disease 
Tier III  At risk  High-risk for accelerated atherosclerosis: 
 epidemiological  evidence 
Post-cancer treatment 
Congenital heart disease 
Kawasaki disease without detected coronary involvement 
CAD: coronary artery disease 
 
Plus 
Step 1. 
Risk stratification 
by disease 
process 
 
Step 2. 
Assess all 
CV risk factors 
 
If ≥2 additional 
comorbidities: 
→ Advance  to  next 
higher risk tier 
Tier I: high risk 
• Homozygous FH 
• Diabetes melitus type 1 
• Chronic kidney disease/ESRD 
• After orthotopic heart transplantation 
• Kawasaki disease with current coronary 
artery aneurysms 
Tier II: moderate risk 
• Heterozygous FH 
• Chronic inflammatory disease 
• Kawasaki disease with regressed coronary
aneurysms 
• Type 2 diabetes mellitus 
 
Tier III: at risk 
• Congenital heart disease 
• Kawasaki disease without detected   
coronary involvement 
• Cancer treatment survivors 
 
Step 3. 
Tier-specific 
cutpoints/ 
treatment 
goals 
 
Tier I: high risk 
• BMI ≤85 percentile for age/sex 
• BP  ≤90 percentile for age/sex 
• LDL cholesterol  ≤100 mg/dL 
• FG <100 mg/dL, HgbA1c <7 percent 
 
Tier II: moderate risk 
• BMI ≤90 percentile for age/sex 
• BP  ≤95 percentile for age/sex/height 
• LDL cholesterol  ≤130 mg/dL 
• FG <100 mg/dL, HgbA1c <7 percent 
 
Tier III: at risk 
• BMI ≤95 percentile for age/sex 
• BP  ≤95 percentile +5 mmHg for 
age/sex/height 
• LDL cholesterol  ≤160 mg/dL 
• FG <100 mg/dL, HgbA1c <7 percent 
Step 4. 
Lifestyle change 
Therapeutic lifestyle 
change-(TLC) 
Therapeutic lifestyle 
change-(TLC) 
Therapeutic lifestyle 
change-(TLC) 
Step 5. 
Drug therapy 
Disease-specific 
management 
If goals not met, 
consider medication 
If goals not met, 
consider medication 
Cardiovascular risk factors/comorbidities 
• Fasting lipid profile 
• Smoking history 
• Family history of early CAD in expanded 1st-degree pedigree (male  ≤55 years; female  ≤65 years) 
• Blood pressure (3 separate occasions), interpreted for age/sex/height 
• BMI 
• Fasting glucose 
• Physical activity history 
Fig. 3. Risk-stratification and treatment algorithm for high-risk pediatric populations. Detailed informations on the treatment recommen-
dations are available at Ref.
40)41) Step 4-for tier I, initial management is therapeutic lifestyle change plus disease-specific management, while
for tiers II and III, initial management is therapeutic lifestyle change; Step 5-for tiers II and III, if goals are not met after initial management,
consider medication. FH: familial hypercholesterolemia, ESRD: end-stage renal disease, CV: cardiovascular, CAD: coronary artery disease,
BP: blood pressure, LDL: low-density lipoprotein, FG: fasting glucose, HgbA1c: hemoglobin A1C, ht: height, pt: patient. 
Yes  Yes  No No  
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dations were peer reviewed and then endorsed by the 
American Academy of Pediatrics.
40)41) As summarized 
in Table 4, the eight identified diseases or states have 
been categorized in three risk tiers (“high”, “moderate”, 
“at risk”) based upon risk for CVD.   
For children at the highest risk (tier I), the interven-
tion strategy regards the diagnosis as a “coronary heart 
disease equivalent” with recommendations for risk re-
duction similar to secondary prevention guidelines for 
adults with established coronary disease. For tier II, 
complete risk factor assessment is recommended with 
specific defined therapeutic goals. For children with 
diagnoses in tier III, the focus is on complete risk fac-
tor assessment with therapeutic goals as defined for 
children in general.   
Recommendations for evaluation and treatment
40)41) 
are summarized in the following treatment algorithm 
(Fig. 3).  
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